-+ 0.00%
-+ 0.00%
-+ 0.00%

Oruka Therapeutics Announces ORKA-002 Interim Phase 1 Results Supporting Potential Infrequent Dosing And Updates ORKA-001 EVERLAST Program With EVERLAST-B Trial Initiation

Benzinga·01/12/2026 12:06:28
Listen to the news
  • ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa
  • Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa
  • First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027